Radioimmunoconjugate

Radioimmunoconjugate is a type of radioimmunotherapy that involves the use of radioactive substances in combination with monoclonal antibodies. These substances are designed to target specific cancer cells, allowing for a more targeted approach to cancer treatment.

Overview[edit | edit source]

Radioimmunoconjugates are created by attaching a radioactive substance to a monoclonal antibody. The antibody is designed to target a specific protein found on the surface of cancer cells. Once the antibody binds to the protein, the radioactive substance can deliver a lethal dose of radiation directly to the cancer cell, minimizing damage to healthy cells.

Types of Radioimmunoconjugates[edit | edit source]

There are several types of radioimmunoconjugates currently in use or under investigation for the treatment of various types of cancer. These include:

Ibritumomab tiuxetan (Zevalin): This radioimmunoconjugate is used for the treatment of non-Hodgkin lymphoma.
Tositumomab (Bexxar): This radioimmunoconjugate is also used for the treatment of non-Hodgkin lymphoma.
Lutetium Lu 177 dotatate (Lutathera): This radioimmunoconjugate is used for the treatment of neuroendocrine tumors.

Side Effects[edit | edit source]

Like all cancer treatments, radioimmunoconjugates can cause side effects. These can include:

Patients should discuss potential side effects with their healthcare provider before starting treatment.

Future Research[edit | edit source]

Research is ongoing to develop new radioimmunoconjugates and to find new uses for existing ones. This includes research into the use of radioimmunoconjugates for the treatment of other types of cancer, such as breast cancer and prostate cancer.

Radioimmunoconjugate Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.